Skip to main content
Log in

Treatment efficacy of etanercept and MTX combination therapy for ankylosing spondylitis hip joint lesion in Chinese population

  • Original Article
  • Published:
Rheumatology International Aims and scope Submit manuscript


To investigate the efficacy of etanercept and MTX (methotrexate) combination therapy in Chinese patients with ankylosing spondylitis hip joint lesion, the possible courses and maintenance protocol, altogether 97 ankylosing spondylitis patients fulfilling the modified New York criteria with hip joint lesion were enrolled in a 12-month trial treated with combined etanercept and MTX. All these patients were required to be poor responders to SSZ (Sulfasalazine) or MTX therapy for 6 consecutive months or the longer. Etanercept was administered subcutaneously twice a week at a fixed dosage of 25 mg for the first six months, followed by 25 mg once a week in patients with good control of both symptoms and radiological progression, or twice a week for another six months in patients with BASDAI> or = 4. Combined MTX was administered intravenously once a week at the dosage of 15 mg. Demographics, clinical and laboratory features, physical function and quality of life using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), the Bath Ankylosing Spondylitis Functional Index (BASFI), Harris hip score, and radiological assessment using the BASRI-hip index were recorded. Most patients achieved pain release at the end point of assessment. Significant improvement in Bath AS Disease Activity Index (BASDAI) (P < 0.05), Bath AS Functional Activity Index (BASFI) (P < 0.05), and Harris hip score (P < 0.05) was demonstrated. Radiographic progression was recorded as no exacerbation or alleviated. Larger interval between two etanercept administrations would provide similar advantages to standard method and possibly less adverse events if MTX was combined. Etanercept and MTX combination therapy was beneficial to ankylosing spondylitis patients with hip joint lesion, and staged dosage deduction in the long term proved to be effective as well as adverse event preventing.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others


  1. Brophy S, Mackay K, Al-Saidi A, Taylor G, Calin A (2002) The natural history of ankylosing spondylitis as defined by radiological progression. J Rheumatol 29:1236–1243

    PubMed  Google Scholar 

  2. Gran JT, Husby G (1993) The epidemiology of ankylosing spondylitis. Semin Arthritis Rheum 22:319–334

    Article  PubMed  CAS  Google Scholar 

  3. Zink A, Braun J, Listing J, Wollenhaupt J (2000) Disability and handicap in rheumatoid arthritis and ankylosing spondylitis. J Rheumatol 27:613–622

    PubMed  CAS  Google Scholar 

  4. Ariza-Ariza R, Hernandez-Cruz B, Navarro-Sarabia F (2003) Physical function and health-related quality of life of Spanish patients with ankylosing spondylitis. Arthritis Rheum 49:483–487

    Article  PubMed  Google Scholar 

  5. Boonen A, Chorus A, Miedema H, van der Heijde D, van der Tempel H, van der Linden S (2001) Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients. Ann Rheum Dis 60:353–358

    Article  PubMed  CAS  Google Scholar 

  6. Boonen A, de Vet H, van der Heijde D, van der Linden S (2001) Work status and its determinants among patients with ankylosing spondylitis. A systematic literature review. J Rheumatol 28:1056–1062

    PubMed  CAS  Google Scholar 

  7. Van der Heijde DM, Revicki DA, Gooch KL, Wong RL, Kupper H, Harnam N et al (2009) Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis. Arthritis Res Ther 11(4):R124

    Article  PubMed  Google Scholar 

  8. Dagfinrud H, Mengshoel AM, Hagan KB, Loge JH, Kvien TK (2004) Health status of patients with ankylosing spondylitis: a comparison with the general population. Ann Rheum Dis 63:1605–1610

    Article  PubMed  CAS  Google Scholar 

  9. Elkayam O, Litinsky I, Levartovsky D, Caspi D (2008) The changing face of spondyloarthropathies under TNF a blockade. Open Rheumatol J 2:53–57

    Article  PubMed  CAS  Google Scholar 

  10. Braun J, Pham T, Sieper J, Davis J, van der Linden S, Dougados M, van der Heijde D, ASAS Working Group (2003) International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 62:817–824

    Article  PubMed  CAS  Google Scholar 

  11. van der Heijde D, Dijkmans B, Geusens P, Sieper J, De Woody K, Williamson P, Braun J (2005) Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 52:582–591

    Article  PubMed  Google Scholar 

  12. Paul S, Keat A (2005) Assessment of patients with spondyloarthropathies for treatment with tumour necrosis factor alpha blockade. Rheumatology 44:17–23

    Article  PubMed  CAS  Google Scholar 

  13. Van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27:361–368

    Article  PubMed  Google Scholar 

  14. Mackay K, Brophy S, Mack C, Doran M, Calin A (2000) The development and validation of a radiographic grading system for the hip in ankylosing spondylitis: the bath ankylosing spondylitis radiology hip index. J Rheumatol 27:2866–2872

    PubMed  CAS  Google Scholar 

  15. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21:2286–2291

    PubMed  CAS  Google Scholar 

  16. Calin A, Garrett S, Whitelock H, Kennedy LG, O’Hea J, Mallorie P, Jenkinson T (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21:2281–2285

    PubMed  CAS  Google Scholar 

  17. Harris WH (1969) Traumatic arthritis of the hip after dislocation and acetabular fractures: treatment by mold arthroplasty. An end-result study using a new method of result evaluation. J Bone Joint Surg Am 51(4):737–755

    PubMed  CAS  Google Scholar 

  18. Calin A, Elswood J (1988) The relationship between pelvic, spinal and hip involvement in ankylosing spondylitis-one disease process or several? Br J Rheumatol 27:393–395

    Article  PubMed  CAS  Google Scholar 

  19. Gensler LS, Ward MM, Reveille JD, Learch TJ, Weisman MH, Davis JC Jr (2008) Clinical, radiographic and functional differences between juvenile-onset and adult-onset ankylosing spondylitis: results from the PSOAS cohort. Ann Rheum Dis 67:233–237

    Article  PubMed  CAS  Google Scholar 

  20. Baraliakos X, Listing J, Brandt J, Haibel H, Rudwaleit M, Sieper J, Braun J (2006) Radiographic progression in patients with ankylosing spondylitis after 4 years of treatment with the anti-TNF-a antibody infliximab. Rheumatology 45:129–138

    Google Scholar 

  21. Keat A, Barkham N, Bhalla A, Gaffney K, Marzo-Ortega H, Paul S, Rogers F, Somerville M, Sturrock R, Wordsworth P, BSR Standards, Guidelines and Audit Working group (2005) BSR guidelines for prescribing TNF-alpha blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology. Rheumatology 44:939–947

    Article  PubMed  CAS  Google Scholar 

  22. Ruof J, Stucki G (1999) Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: a literature review. J Rheumatol 26:966–970

    PubMed  CAS  Google Scholar 

  23. Russell AS, Orozco JH, Maksymowych WP (2002) The dosage of infliximab in the treatment of ankylosing spondylitis: dollars and sense. Clin Exp Rheumatol 20(Suppl 28):s135–s136

    PubMed  CAS  Google Scholar 

  24. Sidirooulos P, Kritikos HD, Siakka P, Mamoulaki M, Kouroumali H, Voudouris K, Boumpas DT (2005) Low dose of infliximab is inadequate in most patients with spondylarthropathies. Clin Exp Rheumatol 23:513–516

    Google Scholar 

  25. Jois RN, Leeder J, Gibb A, Gaffney K, Macgregor A, Somerville M, Scott DG (2006) Low-dose infliximab treatment for ankylosing spondylitis clinically and cost effective. Rheumatology (Oxford) 45:1566–1569

    Article  CAS  Google Scholar 

  26. Keeling S, Oswald A, Russell AS, Maksymowych WP (2006) Prospective observational analysis of the efficacy and safety of low-dose (3 mg/Kg) infliximab in ankylosing spondylitis: 4-year follow up. J Rheumatol 33:558–561

    PubMed  CAS  Google Scholar 

  27. Lee SH, Lee YA, Hong SJ, Yang HI (2008) Etanercept 25 mg/week is effective enough to maintain remission for ankylosing spondylitis among Korean patients. Clin Rheumatol 27:179–181

    Article  PubMed  Google Scholar 

  28. Gadsby K, Deighton C (2007) Characteristics and treatment responses of patients satisfying the BSR guidelines for anti-TNF in ankylosing spondylitis. Rheumatology (Oxford) 46:439–441

    Article  CAS  Google Scholar 

Download references


The authors have declared no conflicts of interest.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Liuqin Liang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lian, F., Yang, X., Liang, L. et al. Treatment efficacy of etanercept and MTX combination therapy for ankylosing spondylitis hip joint lesion in Chinese population. Rheumatol Int 32, 1663–1667 (2012).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: